SecBot SecBot
8-K ·Filed Nov 5, 2026

CYRX

Cryoport, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed11d 6h ago SEC0001104659-26-123381
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and continued improvement in adjusted EBITDA suggest Cryoport is on a path to profitability. Monitor the Q4 2026 launch of the Santa Ana Global Supply Chain Center and any further BLA/MAA filings from clients, as these could drive additional commercial CGT revenue.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$19.10
T+0 close · Nov 5, 2026 · via day close
Latest settled
+4.14%
T+5 · $19.89
Vs SPY
+1.54%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $19.10entry
  2. T+1 · 8d ago +7.17%α +4.81% · $20.47
  3. T+5 · 4d ago +4.14%α +1.54% · $19.89
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cryoport reported Q3 2026 revenue of $50.4 million, up 13% year-over-year, and a GAAP net loss per share of $0.23, narrower than the prior year's $0.28 loss. The company raised its full-year 2026 revenue guidance to $196M-$200M, above the prior range of $192M-$196M, reflecting continued momentum in commercial cell and gene therapy support and Life Sciences Services growth.

Key Financial Metrics

EPS
−$0.23
Revenue
$50.4M
est $48.7M · +3.5% · +13.0% YoY
Guidance
$196M-$200M
raised
Gross Margin
46.2%

Key Facts

  • Q3 2026 total revenue $50.4M, up 13% year-over-year from $44.6M
  • Commercial CGT revenue grew 28% YoY to $10.1M
  • Life Sciences Services revenue $29.2M, up 16% YoY
  • Life Sciences Products revenue $21.2M, up 9% YoY
  • GAAP net loss per share $0.23 vs $0.28 in Q3 2025
  • Adjusted EBITDA from continuing operations improved to negative $0.2M from negative $2.1M
  • Full-year 2026 revenue guidance raised to $196M-$200M from $192M-$196M
  • Supporting 810 global clinical trials and 24 commercially approved CGTs as of September 30, 2026

Financial Impact

Revenue growth of 13% YoY to $50.4M; guidance raised by $4M at midpoint to $198M; adjusted EBITDA loss narrowed by $1.9M YoY

revenuenet lossadjusted EBITDAguidance

Segment Breakdown

SegmentRevenueGrowth
Life Sciences Services$29.2M+16.0%
Life Sciences Products$21.2M+9.0%

Risk Factors

  • Company remains unprofitable on a GAAP basis with a net loss from continuing operations of $8.5M
  • Dependence on client regulatory approvals for commercial CGT revenue growth
  • Execution risk related to new Global Supply Chain Center openings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
8-K Data (Synthetic)0001104659-26-123381

Track record

10 reports on CYRX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $19.89 Now $19.80 −0.45% settles Nov 20
  2. Nov 10, 20266d ago 144 Neutral 3/10 Entry $20.56 Now $19.80 −3.70% settles Nov 18
  3. Nov 9, 20267d ago 144 Neutral 2/10 Entry $20.74 Now $19.80 −4.53% settles Nov 17
  4. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $19.10 to $19.89 Now $19.80 +3.66% ▲ +4.14% +1.54% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $17.83 to $18.29 Now $19.80 +11.05% ▲ +2.58% +1.87% vs SPY
  6. Aug 14, 202613w ago Institutional Cluster Bullish 5/10 Entry $15.25 to $17.13 Now $19.80 +29.84% ▲ +12.33% +13.70% vs SPY
  7. Jun 21, 202621w ago Institutional Cluster Mixed 4/10 Entry $14.77 to $16.00 Now $19.80 +34.06% ▲ +8.33% +10.40% vs SPY
  8. Jun 12, 202622w ago Insider Cluster Neutral 4/10 Entry $14.83 to $14.77 Now $19.80 +33.51% ▼ −0.40% +0.98% vs SPY
  9. Mar 16, 202635w ago Insider Cluster Neutral 3/10 Entry $8.00 to $8.15 Now $19.80 +147.50% ▲ +1.88% +3.92% vs SPY
  10. Mar 16, 202635w ago Insider Cluster Neutral 4/10 Entry $8.00 to $8.15 Now $19.80 +147.50% ▲ +1.88% +3.92% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (10h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026